These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1934250)

  • 1. A randomized study of epirubicin at four different dose levels in advanced breast cancer. Feasibility of myelotoxicity prediction through single blood-sample measurement.
    Jakobsen P; Bastholt L; Dalmark M; Pfeiffer P; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS; Mouridsen HT
    Cancer Chemother Pharmacol; 1991; 28(6):465-9. PubMed ID: 1934250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple-dose pharmacokinetics of epirubicin at four different dose levels: studies in patients with metastatic breast cancer.
    Jakobsen P; Steiness E; Bastholt L; Dalmark M; Lorenzen A; Petersen D; Gjedde SB; Sandberg E; Rose C; Nielsen OS
    Cancer Chemother Pharmacol; 1991; 28(1):63-8. PubMed ID: 2040035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients.
    Danesi R; Innocenti F; Fogli S; Gennari A; Baldini E; Di Paolo A; Salvadori B; Bocci G; Conte PF; Del Tacca M
    Br J Clin Pharmacol; 2002 May; 53(5):508-18. PubMed ID: 11994057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin. Clinical pharmacology and dose-effect relationship.
    Robert J
    Drugs; 1993; 45 Suppl 2():20-30. PubMed ID: 7693418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic-pharmacodynamic relationships between pirarubicin exposure and hematotoxicity: clinical application using only one blood sample.
    Leca FR; Marchiset-Leca D; Galeani A; Noble A; Catalin J
    Anticancer Drugs; 1998 Jul; 9(6):503-9. PubMed ID: 9877237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contradistinction between doxorubicin and epirubicin: in-vivo metabolism, pharmacokinetics and toxicodynamics after single- and multiple-dosing in rats.
    Ramanathan-Girish S; Boroujerdi M
    J Pharm Pharmacol; 2001 Jul; 53(7):987-97. PubMed ID: 11480551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity.
    Venturini M; Lunardi G; Del Mastro L; Vannozzi MO; Tolino G; Numico G; Viale M; Pastrone I; Angiolini C; Bertelli G; Straneo M; Rosso R; Esposito M
    J Clin Oncol; 2000 May; 18(10):2116-25. PubMed ID: 10811677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.
    Bastholt L; Dalmark M; Gjedde SB; Pfeiffer P; Pedersen D; Sandberg E; Kjaer M; Mouridsen HT; Rose C; Nielsen OS; Jakobsen P; Bentzen SM
    J Clin Oncol; 1996 Apr; 14(4):1146-55. PubMed ID: 8648369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy.
    Barker IK; Crawford SM; Fell AF
    J Chromatogr B Biomed Appl; 1996 Jun; 681(2):323-9. PubMed ID: 8811443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
    Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
    J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
    Colucci G; Romito S; Gebbia V; Pacilio G; Giotta F; Testa A; Pezzella G; Durini E; Agostara B; Cariello S
    Br J Cancer; 1995 Nov; 72(5):1245-50. PubMed ID: 7577476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of quinidine and epirubicin in the treatment of advanced breast cancer.
    Jones RD; Kerr DJ; Harnett AN; Rankin EM; Ray S; Kaye SB
    Br J Cancer; 1990 Jul; 62(1):133-5. PubMed ID: 2390473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of epirubicin and its metabolite epirubicinol in saliva and plasma by HPLC.
    Dodde WI; Maring JG; Hendriks G; Wachters FM; Groen HJ; de Vries EG; Uges DR
    Ther Drug Monit; 2003 Aug; 25(4):433-40. PubMed ID: 12883225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and toxicity of two schedules of high dose epirubicin.
    Tjuljandin SA; Doig RG; Sobol MM; Watson DM; Sheridan WP; Morstyn G; Mihaly G; Green MD
    Cancer Res; 1990 Aug; 50(16):5095-101. PubMed ID: 2379173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.
    Bontenbal M; Andersson M; Wildiers J; Cocconi G; Jassem J; Paridaens R; Rotmensz N; Sylvester R; Mouridsen HT; Klijn JG; van Oosterom AT
    Br J Cancer; 1998 Jun; 77(12):2257-63. PubMed ID: 9649142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose 4'-epiadriamycin for treatment of breast cancer refractory to standard dose anthracycline chemotherapy: achievement of second responses.
    Bezwoda WR; Dansey R; Seymour L
    Oncology; 1990; 47(1):4-8. PubMed ID: 2300383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical toxicity of 4'-epi-doxorubicin (epirubicin).
    Ganzina F; Di Pietro N; Magni O
    Tumori; 1985 Jun; 71(3):233-40. PubMed ID: 3861022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics of epirubicin in cancer patients].
    Ohno T; Shimoyama T; Kimura K; Yamada H
    Gan To Kagaku Ryoho; 1986 May; 13(5):1881-6. PubMed ID: 3458430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline pharmacokinetics. Limited sampling model for plasma level monitoring with special reference to epirubicin (Farmorubicin).
    Eksborg S
    Acta Oncol; 1990; 29(3):339-42. PubMed ID: 2363946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.